Riskpilot← Back to searchSign inGet full accessHAUG APOTEK AS
ASActiveOrg 926404180Øvre Klekkenvei 53, 3514 HønefossRetail sale of pharmaceutical products · NACE 4773Est. 20215 employees
Revenue 2024
NOK 11,7M
+13% vs 2023
EBITDA margin
-4.7%
-87% vs 2023
Equity ratio
-82.7%
Financial strength
Net profit 2024
NOK -862K
-26% vs 2023
| Revenue | NOK 11,7M | +13% |
| EBITDA | NOK -552K | -87% |
| Net profit | NOK -862K | -26% |
| Total assets | NOK 2,1M | +0% |
| Equity | NOK -1,7M | -18% |
| Employees | 5 | — |
Legal name
HAUG APOTEK AS
Org number
926404180
Legal form
Aksjeselskap
NACE code
4773 · Retail sale of pharmaceutical products
Founded
18. januar 2021
Share capital
NOK 3 500 000
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap.
Company purpose
Eie og drive apotek og alt hva hermed står i forbindelse.
Address
Øvre Klekkenvei 53, 3514 Hønefoss
Phone
+4731912550
Email
haug@dittapotek.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 3 787 | 8 112 | 10 307 | 11 694 |
| Staff expenses | −1 718 | −2 347 | −2 546 | −3 047 |
| EBITDA | −1 039 | −668 | −294 | −552 |
| Depreciation & amort. | −111 | −196 | −196 | −197 |
| EBIT | −1 149 | −864 | −490 | −749 |
| Net financials | −55 | −112 | −193 | −114 |
| Profit before tax | −1 205 | −976 | −683 | −862 |
| Tax | −0 | −0 | −0 | −0 |
| Net profit | −1 205 | −976 | −683 | −862 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 2 893 | 2 363 | 2 074 | 2 080 |
| Equity | −800 | −1 176 | −1 459 | −1 721 |
| Long-term debt | 1 756 | 1 391 | 1 017 | 620 |
| Short-term debt | 1 937 | 2 147 | 2 515 | 3 181 |
| Total debt | 3 693 | 3 538 | 3 533 | 3 801 |
EBITDA margin
-4.7%
This company
15.8%
Market median
-130% vs market
20212024
Equity ratio
-82.7%
This company
38.2%
Market median
-316% vs market
20212024
Return on equity
-86223200.0%
This company
18.4%
Market median
-468604448% vs market
20212024
Net profit margin
-7.4%
This company
8.1%
Market median
-191% vs market
20212024
Asset turnover
5.62×
This company
1.12×
Market median
+402% vs market
20212024
Debt / equity
2.21×
This company
0.62×
Market median
-256% vs market
20212024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
SS Chief Executive Officer | Chief Executive Officer | 2021 |
SH Chief Executive Officer | Chief Executive Officer | 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Chairman | 2021 | |
| Board of Directors | 2021 | |
| Board of Directors | 2021 | |
| Board of Directors | 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 33.3% | 33.3% | 2024 | |
| Company | 33.35% | 33.35% | 2024 | |
| Company | 33.35% | 33.35% | 2024 | |
| Company | 10% | 10% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Apoinvest Holding As
HAUG APOTEK AS Board members of HAUG APOTEK AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Stina Sand Bowitz | Chief Executive Officer | 0 companies |
| Syed Hassan Mujtaba | Chief Executive Officer | 0 companies |
| Morten Frogner | Chairman | 0 companies |
| Jan Arne Frogner | Board of Directors | 0 companies |
| Einar Mathias Teigen Rasch-Halvorsen | Board of Directors | 0 companies |
| Gulzeb Aziz | Board of Directors | 0 companies |